Retroviral vector having immune-stimulating activity
AssigneeDenovo Biopharma LLC
InventorsHarry E. Gruber, Douglas J. Jolly, Amy H. Lin, Joan M. Robbins, Derek G. Ostertag
Life of this patent
Estimating the term…
Abstract
The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
Claims11
A recombinant replication competent retroviral vector comprising a sequence encoding at least one agent that down regulates an immune inhibitory agent, wherein the at least one agent is a sequence encoding an antibody to a programmed death ligand (PDL) wherein the replication competent retroviral vector has a genome of the general structure from 5′ to 3′ comprising a long terminal repeat (LTR)-gag sequence-pol sequence-env sequence-at least one expression cassette-LTR, wherein said recombinant retroviral vector comprises a first cassette comprising a polIII promoter operably linked to a first inhibitory nucleic acid sequence, and a second cassette comprising a mini-promoter operably linked to the sequence encoding the antibody to the PDL.
Dependencies are inferred from the claim text.